RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPTGet Free Report) has earned an average rating of “Hold” from the thirteen research firms that are covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.67.

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Barclays lowered shares of RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $13.00 to $4.00 in a research report on Friday, May 10th. Wolfe Research restated a “peer perform” rating on shares of RAPT Therapeutics in a research report on Tuesday, May 14th. HC Wainwright restated a “neutral” rating on shares of RAPT Therapeutics in a research report on Wednesday, April 10th. Finally, Guggenheim lowered shares of RAPT Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 10th.

View Our Latest Analysis on RAPT Therapeutics

RAPT Therapeutics Stock Up 1.6 %

Shares of NASDAQ:RAPT opened at $3.14 on Tuesday. The firm has a fifty day moving average of $5.41 and a two-hundred day moving average of $13.12. The firm has a market capitalization of $109.60 million, a P/E ratio of -1.02 and a beta of 0.40. RAPT Therapeutics has a 12-month low of $2.99 and a 12-month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPTGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.01). Equities research analysts expect that RAPT Therapeutics will post -2.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently made changes to their positions in the stock. Swiss National Bank boosted its holdings in RAPT Therapeutics by 9.6% during the third quarter. Swiss National Bank now owns 49,100 shares of the company’s stock worth $816,000 after purchasing an additional 4,300 shares during the last quarter. FMR LLC lifted its stake in RAPT Therapeutics by 7.4% in the third quarter. FMR LLC now owns 4,499,293 shares of the company’s stock valued at $74,778,000 after acquiring an additional 308,804 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in RAPT Therapeutics by 75.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 135,045 shares of the company’s stock valued at $2,244,000 after acquiring an additional 58,049 shares during the last quarter. Braidwell LP lifted its stake in RAPT Therapeutics by 10.0% in the third quarter. Braidwell LP now owns 1,082,512 shares of the company’s stock valued at $17,991,000 after acquiring an additional 98,112 shares during the last quarter. Finally, Euclidean Capital LLC raised its position in shares of RAPT Therapeutics by 15.2% in the third quarter. Euclidean Capital LLC now owns 657,899 shares of the company’s stock valued at $10,934,000 after purchasing an additional 86,666 shares during the period. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

(Get Free Report

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Read More

Analyst Recommendations for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.